Centene Corp presents a distinctive profile among managed care operators, with systematic screening highlighting a significant valuation discount at 0.15x price-to-sales alongside operational challenges reflected in negative profitability metrics. The company trades at 1.01x book value with a market capitalization of $30.7 billion, positioning near tangible asset levels while peers UNH, ELV, and HUM typically command premium valuations.

Revenue momentum demonstrates notable strength: the 17.02% year-over-year growth rate substantially outpaces typical healthcare services expansion, indicating successful membership acquisition or contract wins. The current price of $62.22 sits within 10% of the 52-week high of $69.36, suggesting technical resilience despite fundamental headwinds. The balance sheet maintains a debt-to-equity ratio of 0.87 with a current ratio of 1.1, providing adequate liquidity coverage.

Critical profitability concerns emerge across multiple dimensions. The model flags a negative ROE of -24.03%, ROI of -13.39%, and ROA of -6.32%, with the -$10.44 earnings per share indicating substantial net losses. Operating margin compression to -3.68% and net margin of -3.25% contrast sharply with the 7.18% gross margin, pointing to elevated SG&A or medical cost ratio pressures common during integration periods or membership mix shifts.

• Revenue acceleration potentially driven by Medicaid redetermination tailwinds
• Valuation discount provides asymmetric risk profile versus established peers
• Profitability restoration timeline remains the central analytical question

Relative to UnitedHealth, Elevance, and Humana, Centene's government-focused business model historically operates at lower margins but serves underserved populations. The beta of 1.1 reflects moderate volatility characteristics within the managed care universe.